HIKMA PHARMACEUTIC.LS-,10/ GB00B0LCW083 /
2024-08-28 10:59:26 PM | Chg. -0.200 | Volume | Bid10:59:26 PM | Ask10:59:26 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
23.600EUR | -0.84% | - Turnover: - |
23.600Bid Size: - | 23.800Ask Size: - | 5.22 bill.EUR | - | - |
Assets
|
2019 IFRS in mill. USD |
2020 IFRS in mill. USD |
2021 IFRS in mill. USD |
2022 IFRS in mill. USD |
2023 IFRS in mill. USD |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 912 | 1,009 | 1,146 | 1,081 | 1,096 | ||||||
Intangible Assets | 552 | 587 | 607 | 735 | 712 | ||||||
Long-Term Investments | 43 | 48 | - | - | 10 | ||||||
Fixed Assets | 2,082 | 2,213 | 2,278 | 2,472 | 2,580 | ||||||
Inventories | 568 | 757 | 695 | 776 | 891 | ||||||
Accounts Receivable | 719 | 756 | 816 | 809 | 824 | ||||||
Cash and Cash Equivalents | 442 | 323 | 426 | 270 | 205 | ||||||
Current Assets | 1,848 | 1,922 | 2,094 | 1,999 | 2,100 | ||||||
Total Assets | 3,930 | 4,135 | 4,372 | 4,471 | 4,680 |
Liabilities
|
2019 IFRS in mill. USD |
2020 IFRS in mill. USD |
2021 IFRS in mill. USD |
2022 IFRS in mill. USD |
2023 IFRS in mill. USD |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 473 | 470 | 468 | 476 | 568 | ||||||
Long-term debt | 48 | 692 | 725 | 1,135 | 975 | ||||||
Liabilities to Banks | 617 | 850 | - | - | - | ||||||
Provisions | 43 | 59 | 55 | 51 | 184 | ||||||
Liabilities | 1,801 | 1,987 | 1,905 | 2,323 | 2,471 | ||||||
Share Capital | 41 | 41 | - | - | - | ||||||
Total Equity | 2,117 | 2,135 | 2,453 | 2,135 | 2,198 | ||||||
Minority Interests | 12 | 13 | 14 | 13 | 11 | ||||||
Total liabilities equity | 3,930 | 4,135 | 4,372 | 4,471 | 4,680 |
Income Statement
|
2019 IFRS in mill. USD |
2020 IFRS in mill. USD |
2021 IFRS in mill. USD |
2022 IFRS in mill. USD |
2023 IFRS in mill. USD |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 2,207 | 2,341 | 2,553 | 2,517 | 2,875 | ||||||
Depreciation (total) | - | 2 | - | - | - | ||||||
Operating Result | 493 | 579 | 582 | 282 | 367 | ||||||
Interest Income | - | - | -39 | -52 | -88 | ||||||
Income Before Taxes | 491 | 558 | - | - | - | ||||||
Income Taxes | -4 | -128 | 124 | 42 | 89 | ||||||
Minority Interests Profit | -1 | 1 | 1 | -3 | 2 | ||||||
Net Income | 486 | 431 | 421 | 188 | 190 |
Per Share
Cash Flow
|
2019 IFRS in mill. USD |
2020 IFRS in mill. USD |
2021 IFRS in mill. USD |
2022 IFRS in mill. USD |
2023 IFRS in mill. USD |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 472 | 464 | 638 | 530 | 608 | ||||||
Cash Flow from Investing Activities | -151 | -283 | -238 | -607 | -333 | ||||||
Cash Flow from Financing | -155 | -298 | -287 | -58 | -337 | ||||||
Decrease / Increase in Cash | 166 | -117 | - | - | - | ||||||
Employees | 8,578 | 8,681 | 8,703 | 8,835 | - |